Vontobel Certificates


  • Symbol BULL NOVOB X3 VON
Price on
3X Long Index linked to Novo Nordisk ASDKK 
Please note that this is an indication.


Novo Nordisk A/S

Important legal information

Novo Nordisk is a global healthcare company with leading positions in diabetes care. In addition to diabetes, the company focuses on treatment for haemophilia, growth disorders and obesity. Novo Nordisk classifies itself as a “focused” healthcare company due to its focus on these niches selected areas.

Diabetes is generating the majority of Novo Nordisk’s revenues. According to the company, the number of diabetes cases will increase globally and without global action, there could be more than 592 million people living with diabetes by the year 2035 (source: Novo Nordisk webpage).

Novo Nordisk boasts high market shares in its respective areas of operation:

- 28% market share in diabetes care
- 47% insulin volume market share with leadership position across all regions
- 45% modern and new-generation insulin volume market share
(Source: Novo Nordisk Investor Presentation)

Novo Nordisk A/S has long been a favorite stock to own among Nordic investors given its growth profile, profitability as well as defensive characteristics (e.g. low cyclicality and debt free balance sheet). Over the past 10 years alone, the share price of Novo Nordisk A/S has increased by more than 800%. Share price hit all time high of DKK 415 in August 2015. However, the future development remains to be seen.

Recently, the share price of Novo Nordisk A/S has been subject to high volatility. After the announcement of 2015 full year results in February, share price fell from c. DKK 380 to c. DKK 320, a hefty fall of 16%. One major reason for this downfall could have been that the management lowered 2016 financial guidance, which Investors were not expecting. After a few days of hovering around DKK 320 level, a recovery phase started and share price increased back to DKK 390 level in March, up more than 20% from previous low. Currently, the stock trades around DKK 360 level.

Analyst sentiment remains very positive on Novo Nordisk – #11 (61%) retain a “Buy” recommendation, #6 (33%) “Hold” and only #1 (6%) “Sell” recommendation.

Recent volatility offers interesting opportunities for investors to take a view on Novo Nordisk future share price development.